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Sirtuin 2 (SIRT2) and SIRT3 are cytoplasmic and mitochondrial NAD-dependent
deacetylases. SIRT2 and SIRT3 target proteins involved in metabolic, proliferation
and inflammation pathways and have been implicated in the pathogenesis of
neurodegenerative, metabolic and oncologic disorders. Both pro- and anti-inflammatory
effects have been attributed to SIRT2 and SIRT3, and single deficiency in SIRT2 or
SIRT3 had minor or no impact on antimicrobial innate immune responses. Here, we
generated a SIRT2/3 double deficient mouse line to study the interactions between
SIRT2 and SIRT3. SIRT2/3−/− mice developed normally and showed subtle alterations
of immune cell populations in the bone marrow, thymus, spleen, blood and peritoneal
cavity that contained notably more anti-inflammatory B-1a cells and less NK cells.
In vitro, SIRT2/3−/− macrophages favored fatty acid oxidation (FAO) over glycolysis
and produced increased levels of both proinflammatory and anti-inflammatory cytokines.
In line with metabolic adaptation and increased numbers of peritoneal B-1a cells,
SIRT2/3−/− mice were robustly protected from endotoxemia. Yet, SIRT2/3 double
deficiency did not modify endotoxin tolerance. Overall, these data suggest that sirtuins
can act in concert or compensate each other for certain immune functions, a parameter
to be considered for drug development. Moreover, inhibitors targeting multiple sirtuins
developed for clinical purposes may be useful to treat inflammatory diseases.
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INTRODUCTION
Sentinel immune cells like monocytes/macrophages, dendritic cells (DCs) and polymorphonuclear
neutrophils (PMNs) sense microbial- and danger-associated signals through pattern recognition
receptors (PRRs) expressed at cell surface, in endosomes and in cytoplasm. The main families
of PRRs are Toll-like receptors (TLRs), C-type lectin receptors, NOD-like receptors, RIG-I-like
receptors and cytosolic DNA sensors (1, 2). Triggering PRRs through microbial and endogenous
Heinonen et al. SIRT2/SIRT3 Deficiency and Host Defenses
agonists activates mitogen-activated protein kinase (MAPK), NF-
κB and interferon-related factor signal transduction pathways.
Signaling leads to the production of effector molecules, such
as cytokines, critical to activate innate and adaptive immunity.
Tight regulation of inflammation and innate immune responses
is vital for controlling microbial invasion while ensuring prompt
tissue repair and return to homeostasis. Hence, innovative
immunomodulatory therapies have been proposed to fight severe
infections and sepsis (3–8).
Mammals express seven sirtuins (SIRT1-7). Sirtuins are
NAD+-dependent enzymes, originally described as histone
deacetylases (HDACs). Each sirtuin potentially targets thousands
of non-histone proteins (9). SIRT1, SIRT6, and SIRT7 localize
mainly in the nucleus, SIRT2 in the cytoplasm, and SIRT3-5
in the mitochondria. Shuttling between organelles have been
observed for several sirtuins, for example SIRT2 and SIRT3
into the nucleus and SIRT5 into the cytoplasm (10). Besides
a deacetylase activity described for all but SIRT4, sirtuins
function as decrotonylase (SIRT1-3), demyristylase (SIRT2),
ADP-ribosyltransferase (SIRT4, SIRT6), lipoamidase (SIRT4),
demalonylase, deglutarylase, and desuccinylase (SIRT5), and
deacylase (SIRT6) (11).
SIRT2 is the most expressed sirtuin in the brain and
myeloid cells (12, 13). SIRT2 regulates cellular stability and
division by targeting tubulin in the cytoplasm (14) and acting
as a mitotic checkpoint in the nucleus during the G2/M
phase transition (15). SIRT2 is involved in myelogenesis and
other brain functions and is a promising target for treating
neurodegenerative conditions among which Parkinson’s disease
and Huntington’s disease (16). SIRT2 is a tumor suppressor gene
but has also been associated with tumorigenesis (17). SIRT2
is likely linked to disease progression through cell metabolism
regulation. SIRT2 inhibits glycolysis and adipogenesis and
promotes lipolysis, gluconeogenesis and the pentose phosphate
pathway (PPP), possibly in a cell and disease dependent
manner (13, 18–22). Accordingly, SIRT2 plays a role in
obesity, type 2 diabetes and other metabolic disorders (18).
The picture is not clear regarding inflammatory processes.
SIRT2 deficiency has been reported to stimulate, inhibit and
have no effect on the activation NF-κB p65 and MAPKs, the
expression of cytokines and the development of inflammatory
and autoimmune diseases (13, 23–32).
SIRT3 is expressed ubiquitously and its expression increases
upon caloric restriction and other stress conditions. SIRT3 is
the main mitochondrial deacetylase and a major regulator of
cell metabolism. SIRT3 promotes tricarboxylic acid cycle and
electron transport chain, ketogenesis, fatty acid oxidation, brown
adipose tissue thermogenesis and urea cycle (33–37). SIRT3
inhibits oxidative stress by activating isocitrate dehydrogenase
2 (IDH2) and superoxide dismutase 2 (SOD2) (38–40).
Through the regulation of metabolism and redox homeostasis,
SIRT3 protects from age-associated metabolic, cardiovascular
and neurodegenerative diseases. SIRT3 also counteracts the
development of inflammation-related disorders, although some
studies suggest that SIRT3 does not impact on inflammatory
responses (41–46). Finally, SIRT3 was shown to drive both pro-
tumorigenic and tumor-suppressive effects (47).
HDACs may act in concert or compensate each other as
suggested by the role played by SIRT1, HDAC5, HDAC6,
and HDAC9 in dampening regulatory T cells (Tregs) and by
SIRT1, SIRT3, and SIRT6 in regulating metabolic adaptation to
inflammation (48–51). As a consequence, deficiency in several
sirtuins might amplify or reveal phenotypes undetectable in
single knockouts. Indeed, dual deletion of SIRT3 and SIRT5
showed some impact on antimicrobial host defense mechanisms
not seen in - SIRT3 and SIRT5 single deficient mice (43, 52,
53). SIRT2 and SIRT3 do not seem to share targets, but they
both impact on ROS detoxification at different levels. SIRT2
regulates through FOXO1 the transcription of genes encoding
for ROS detoxifying enzymes while SIRT3 regulates the activity
of the enzymes (38–40). Thus, the absence of SIRT2 or SIRT3
could be compensated by an increased activity of the other
sirtuin. To challenge our assumption, we generated a SIRT2/3
double deficient mouse line. We show that the double deletion
of SIRT2 and SIRT3 impacts on some metabolic and immune
parameters not observed in single knockouts. Importantly from a
translational perspective, SIRT2/3 deficient mice were protected
from endotoxemia. This information is valuable considering




Animal experiments were approved by the Service des
Affaires Vétérinaires, Direction Générale de l’Agriculture,
de la Viticulture et des Affaires Vétérinaires (DGAV), état de
Vaud (Epalinges, Switzerland) under authorizations 876.9 and
877.9 and performed according to Swiss and ARRIVE guidelines.
Mice
SIRT2−/− and SIRT3−/− C57BL/6J mice have been described
(54, 55). SIRT3−/− females were crossed with SIRT2−/−
males to obtain 53 female and 47 male SIRT2/3+/− mice.
SIRT2/3+/− mice were crossed to obtain 312 F2 mice. We
identified 7 female and 3 male double knockout mice that were
used to establish the SIRT2/3−/− mouse line. For genotyping
purposes, DNA was extracted and analyzed by PCR using the
Mouse Direct PCR Kit (Bimake, Houston, TX), primers pairs
(Supplementary Information) and a QuantStudioTM 12K Flex
system (Life Technologies, Carlsbad, CA). Mice used in this
study were 7–14-week old, housed under specific pathogen-
free conditions and exempt of mouse hepatitis virus and
murine norovirus.
Cells and Reagents
Bone marrow (BM) cells were cultured for 7 days in RPMI
1640 (Life Technologies, Carlsbad, CA) supplemented with 1%
penicillin-streptomycin (Invitrogen, Carlsbad CA), 10% heat
inactivated fetal bovine serum (FBS; Biochrom GmbH, Berlin,
Germany) and 50 U/ml macrophage colony-stimulating factor
(M-CSF; ImmunoTools, Friesoythe, Germany) to obtain BM
derived macrophages (BMDMs) (56). BMDMs were seeded in
96-well or 24-well plates (2 × 105 or 1 × 106 cells/well) without
Frontiers in Immunology | www.frontiersin.org 2 November 2019 | Volume 10 | Article 2713
Heinonen et al. SIRT2/SIRT3 Deficiency and Host Defenses
M-CSF for stimulation and phagocytosis/killing experiments,
respectively. Peritoneal cells were obtained through a peritoneal
lavage performed using 5ml ice-cold RPMI (57). Cells were
enumerated and seeded in 96-well plates (2 × 105 cells/well)
in RPMI containing 1% penicillin-streptomycin and 10% FBS.
BMDMs and peritoneal cells were stimulated with ultrapure
LPS from Salmonella minnesota (List Biological Laboratories,
Campbell, CA), Pam3CSK4 (EMC microcollections, Tübingen,
Germany), and CpG A 1585 (Microsynth, Balgach, Switzerland).
RNA Analyses
RNA was extracted with the RNeasy kit (Qiagen, Hilden,
Germany) and reverse transcribed with the QuantiTect reverse
transcription kit (Qiagen). Real-time PCR was performed
using primers (Supplementary Information) and KAPA SYBR
Green Fast (Kapa Biosystems, Wilmington, MA) as described
(58). Reactions were run on a QuantStudioTM 12K Flex
system (Life Technologies). Gene expression was normalized to
actin expression.
Western Blot Analyses
Proteins were extracted, submitted to PAGE and transferred to
nitrocellulose membranes as described (59). Membranes were
incubated with primary antibodies against β-actin (4967, Cell
Signaling, Danvers, MA), NF-κB p65 (8242, Cell Signaling)
p44/42 MAPK (ERK1/2; 9102, Cell Signaling), phospho-
p44/42 (ERK1/2; 9101, Cell Signaling), p38 MAPK (9102, Cell
Signaling), phosho-p38 MAPK (9211, Cell Signaling), SIRT2
(ab67299; Abcam, Cambridge, United Kingdom), SIRT3 (5490;
Cell Signaling), α-tubulin (T5168; Sigma-Aldrich, Darmstadt,
Germany), and HRP-coupled secondary antibodies (31430 and
31460; Invitrogen). Blots were revealed with the enhanced
chemiluminescence Western blotting system (Advansta, San
Jose, CA). Images were recorded with the Fusion Fx system
(Viber Lourmat, Collégien, France). Full length blots are
presented in Supplementary Figure 1.
Flow Cytometry
Single cell suspensions were incubated with Fc blocker, stained
with antibodies listed in Supplementary Information and fixed
with 2% paraformaldehyde. Data were acquired with an Attune
Nxt flow cytometer (ThermoFisher, Waltham, MA) and analyzed
using FlowJo 10.2 (FlowJo LLC, Ashland, OR). Gating strategies
are presented in Supplementary Figure 2 and in Heinonen
et al. (52).
Metabolic Activity
Four × 104 BMDMs per well were plated in Seahorse
XFe96 plates. Glycolytic activity, mitochondrial respiration and
mitochondrial flexibility were analyzed using Seahorse Glycolysis
Stress and Mito Fuel Flex Test kits (Agilent, Santa Clara, CA) as
recommended by the manufacturer. Two × 104 BMDMs were
plated in 96-well plates and grown in RPMI (Sigma-Aldrich)
with 5mM glucose. Glucose and lactate were measured with the
Glucose-Glo and Lactate-Glo kits (J6021 and J5021, Promega,
Madison, WI) and luminescence was recorded with a Synergy
plate reader (BioTek, Winooski, VT).
Cytokine Measurements
Cytokines and chemokines were measured in cell supernatant
and plasma by ELISA (IL-6 and TNF: R&D systems,Minneapolis,
MN; IL-10: Mabtech, Nacka Strand, Sweden) or by Luminex
(Mouse Custom ProcartaPlex 17-plex: ENA-78/CXCL5, G-CSF,
IFNγ, IL-1α, IL-1β, IL-3, IL-6, IL-10, IL-12p40, IL-17A, IL-18,
IP-10/CXCL10, KC/CXCL1, MCP-1/CCL2, MIP-1α/CCL3, MIP-
2/CXCL2, TNF) (Invitrogen) and recorded with a bioplex 200
(Bio-Rad, Hercules, CA) (60).
Phagocytosis and Killing Assay
E. coli O18 (E. coli) was grown in brain heart infusion broth
(Oxoid Limited, Hampshire, United Kingdom) and washed in
0.9% NaCl (61). BMDMs were incubated with Fluoresbrite R©
Yellow Green Microspheres (Polysciences Inc., Warrington, PA,
USA) or live E. coli at a bead or bacteria-to-cell ratio of 10:1 for
1 h to quantify phagocytosis and for 6 h to quantify killing as
described (62).
In vivo Models
SIRT2/3+/+ and SIRT2/3−/− male mice (n = 8–10 per group)
were challenged intraperitoneally with 10 mg/kg LPS from E. coli
O111:B4. Blood was collected 0, 1, 3, and 7 days post-challenge to
quantify cytokines by Luminex, analyze cell populations by flow
cytometry, and perform whole blood assays as described (63).
Body weight loss, severity score and survival were monitored at
least twice daily. The severity score was graded from 0 to 6 based
on animal motility and aspect. Two to three operators performed
animal follow-up (64).
Statistical Analyses
Graphics represent data obtained from individual mice (dots),
or box with min to max whiskers. Data from different groups
were analyzed for normal distribution and homogeneity of
variances and compared with the appropriate parametric (two-
tailed unpaired Student’s t-test) or non-parametric (two-tailed
Mann-Whitney test) statistical test. For gravity score, area under
the curve was used for analysis. Survival was analyzed using the
Kaplan-Meier method. P-values were two-sided, and P < 0.05
was considered to indicate statistical significance. ∗P ≤ 0.05; ∗∗P
≤ 0.01; ∗∗∗P ≤ 0.005. Analyses were performed using PRISM
8.0.1 (GraphPad Software, San Diego, CA).
RESULTS
SIRT2/3−/− Mice Develop Without
Abnormalities
SIRT2−/− and SIRT3−/− mice were crossed to generate a F2
population (see Materials and Methods). Among 312 F2 mice,
we identified 10 double knockouts that were used to establish the
SIRT2/3−/− mouse line. The truncation of the Sirt2 and Sirt3
genes and the absence of SIRT2 and SIRT3 protein expression
were confirmed by PCR (Figure 1A) and Western blotting
(Figure 1B). The size of litters (Figure 1C) and the female/male
sex ratio of litters (Figure 1D) were similar in the SIRT2/3+/+,
SIRT2−/−, SIRT3−/−, and SIR2/3−/− mouse lines. The weight
of adult female and male mice were comparable among mouse
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FIGURE 1 | Establishment of a SIRT2/3−/− mouse line. (A) Genotyping of SIRT2/3+/+, SIRT2−/−, SIRT3−/−, and SIRT2/3−/− mice. Genomic DNA was amplified by
PCR using the primer pairs specified on the right. Reaction mixtures were electrophoresed through agarose gels before imaging. (B) Western blot analysis of SIRT2,
SIRT3 and tubulin expression in SIRT2/3+/+ and SIRT2/3−/− BMDMs (Full blots are presented in Supplementary Figure 1). (C,D) Number of individuals (C) and
female/male distribution (D) of SIRT2/3+/+, SIRT2−/−, SIRT3−/− and SIRT2/3−/− litters. (E) Weight of SIRT2/3+/+, SIRT2−/−, SIRT3−/−, and SIRT2/3−/− adult
female and male mice. (F) mRNA expression of SIRT1 and SIRT4-7 in SIRT2/3−/− BMDMs were quantified by RT-qPCR and normalized to actin mRNA. Data are
mean ± SD of eight mice analyzed in triplicate. *P < 0.05.
lines (Figure 1E). Mouse development was normal, and no
macroscopic abnormalities were detected upon autopsy. The
expression levels of Sirt1, 4, 5, and 7 mRNA were not affected
while the expression of Sirt6 mRNA was increased 1.5-fold in
SIRT2/3−/− BMDMs (Figure 1F).
SIRT2/3−/− Mice Have Minor Alterations of
Leukocyte Subpopulations
SIRT2 and SIRT3 are expressed by all major immune cell
subpopulations (13, 43) but their role in the development
of myeloid cells is unknown. We quantified leukocyte
populations in primary and secondary lymphoid organs,
blood and peritoneum of SIRT2/3+/+, SIRT2−/−, SIRT3−/−,
and SIRT2/3−/− mice. In the bone marrow, the number of
CD45+ cells was similar in all mouse lines (Table 1). The
frequency of T cells, conventional DCs (cDCs), plasmacytoid
DCs (pDCs) and granulocytes was not affected in knockout
mouse lines. The proportion of Ly6Clow (alternative) monocytes
was slightly reduced (<10%) in SIRT2/3−/− mice, as it was in
SIRT2−/− and SIRT3−/− mice. In contrast, the frequency of
B cells was 30% higher in SIRT2/3−/− mice. In the thymus,
SIRT2/3−/− mice expressed normal proportions and absolute
numbers of CD4/CD8 double negative (DN) thymocytes,
DN1-DN4 thymocytes, and CD4 and CD8 single positive
thymocytes and 4% less CD4+ CD8+ double positive thymocytes
(Table 2). The spleen of SIRT2/3+/+, SIRT2−/−, SIRT3−/−, and
SIRT2/3−/− mice contained comparable populations of CD4+
and CD8+ T cells and monocytes (Table 3). However, the spleen
of SIRT2/3−/− mice contained 19% more naïve CD4+ T cells
and 11% more B cells, as seen in the bone marrow, but 17%
less CD11c+ DCs and 39% less Ly6G+ granulocytes (Table 3).
Taken all together, SIRT2/3 deficiency had no dramatic impact
on leukocyte development.
Blood leukocytes play a key role in sensing MAMPs/DAMPs
and are quickly recruited to inflamed tissues. The number
of leukocytes and the frequencies of B cells, T cells, PMNs,
monocytes and NK cells were similar in SIRT2/3+/+, SIRT2−/−,
SIRT3−/−, and SIRT2/3−/− mice (Figures 2A,B), although we
could observe an increased frequency of B cells and decreased
frequency of PMNs in the blood of SIRT2/3−/− mice. The
egress of PMNs from the bone marrow follows a circadian
rhythm, a process that is modulated by sirtuins (65). Aged
neutrophils express increased levels of CD11b (66). CD11b mean
fluorescence intensity (MFI) of SIRT2/3+/+ and SIRT2/3−/−
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B220+ B cells 13.2 ± 1.9 15.5 ± 3.8 17.2 ± 0.7 17.4 ± 1.3
CD3+ T cells 4.6 ± 0.9 3.5 ± 1.1 5.2 ± 1.1 3.6 ± 1.1
CD11c+ DCs 3.8 ± 0.3 3.3 ± 0.2 3.8 ± 0.3 3.6 ± 0.2
pCDs 63.6 ± 2.2 64.3 ± 2.6 62.2 ± 0.9 67.4 ± 4.0
cDCs 33.4 ± 2.0 32.8 ± 2.7 34.2 ± 0.9 29.9 ± 3.7
cDC1 (CD11b−) 51.0 ± 2.9 49.7 ± 8.2 48.0 ± 4.6 52.7 ± 3.6
cDC2 (CD11b+) 45.8 ± 2.9 47.4 ± 8.5 48.0 ± 4.6 44.3 ± 3.4
Ly6G+ Ly6C− granulocytes 48.1 ± 3.3 48.2 ± 4.2 44.3 ± 0.9 44.9 ± 1.0
Ly6G− Ly6C+ monocytes 15.4 ± 0.8 15.3 ± 2.4 15.0 ± 0.7 15.3 ± 0.7
Ly6Clow alternative
monocytes
44.9 ± 0.9 40.4 ± 2.0 38.9 ± 2.2 40.7 ± 2.8
Ly6Chigh classical
monocytes
48.0 ± 0.5 51.8 ± 1.7 52.2 ± 1.8 50.1 ± 2.9
Data are mean ± SD of four mice per group and are expressed as the percentage of
CD45+ cells (B220+, CD3+, CD11c+, Ly6G+Ly6C−, Ly6G−Ly6C+) or the percentage
of parental cells. The number of CD45+ cells per leg was 14.4 ± 2.5, 14.9 ± 2.3, 12.0 ±
3.1, and 12.6 ± 4.2 × 106 cells for SIRT2/3+/+, SIRT2−/−, SIRT3−/−, and SIRT2/3−/−
mice. Gray background: P < 0.05 vs. SIRT2/3+/+ mice.









CD4− CD8− 3.3 ± 0.2 3.3 ± 0.3 3.9 ± 0.6 4.1 ± 0.4
DN1 (CD25− CD44+) 20.2 ± 3.2 21.1 ± 0.6 21.9 ± 6.8 21.5 ± 1.7
DN2 (CD25+ CD44+) 21.0 ± 2.4 19.8 ± 2.3 20.9 ± 1.7 21.2 ± 2.1
DN3 (CD25+ CD44−) 35.7 ± 2.5 35.3 ± 1.2 32.6 ± 2.0 32.0 ± 1.1
DN4 (CD25− CD44−) 23.1 ± 1.5 23.8 ± 2.7 24.6 ± 3.6 25.3 ± 1.9
CD4+ CD8+ 84.6 ± 1.2 82.4 ± 0.7 80.9 ± 3.1 81.1 ± 0.2
CD4+ 6.8 ± 0.7 8.1 ± 0.4 8.7 ± 1.9 8.2 ± 0.5
CD8+ 1.6 ± 0.3 2.3 ± 0.2 2.1 ± 0.7 2.0 ± 0.4
Data are mean ± SD of four mice per group expressed as percentage of total thymocytes
(CD4− CD8−, CD4+ CD8+, CD4+, CD8+) or the percentage of CD4− CD8− cells
(CD25− CD44+, CD25+ CD44+, CD25+ CD44−, CD25− CD44−). Thymus weights were
71.3 ± 8.6, 107.0 ± 20.9, 90.5 ± 15.6, and 89.5 ± 5.3mg for SIRT2/3+/+, SIRT2−/−,
SIRT3−/−, and SIRT2/3−/− mice. Gray background: P < 0.05 vs. SIRT2/3+/+ mice.
PMNs was alike (Figure 2C), suggesting that SIRT2 and SIRT3
do no impact on PMNs release from the bone marrow.
The frequency of Ly6Clow, Ly6Cint, and Ly6Chigh monocyte
subpopulations were similar in all mouse lines (Figure 2D).
Hence, the reduced number of Ly6Clow monocytes in the
bone marrow of knockout mice (Table 1) had no perceptible
impact on blood monocytes. CD62L, a homing receptor for
secondary lymphoid organs, is expressed by NK cells at steady-
state (67). CD62L MFI was 1.7- to 2-fold higher in NK cells from
SIRT2/3−/− mice (Figure 2E).
The peritoneal cavity of mice contains mainly B cells, T
cells, macrophages and NK cells (68). Peritoneal macrophages
are divided into large peritoneal macrophages (LPMs) and
small peritoneal macrophages (SPMs). LPMs are self-renewing









B220+ B cells 47.1 ± 0.8 48.9 ± 1.3 47.1 ± 2.5 52.2 ± 2.2
Mature (CD23+ IgD+) 70.0 ± 1.8 67.2 ± 1.6 66.8 ± 2.4 67.3 ± 2.4
Immature (non-CD23+ IgD+) 30.0 ± 1.8 32.8 ± 1.6 33.2 ± 2.4 32.7 ± 2.4
CD3+ T cells (%) 35.6 ± 1.6 36.3 ± 1.9 37.9 ± 2.7 34.0 ± 1.6
CD4+ 56.0 ± 2.0 58.4 ± 1.6 58.1 ± 0.8 59.8 ± 3.0
Naive 50.0 ± 2.0 61.4 ± 4.1 56.6 ± 5.3 59.3 ± 4.5
Memory 18.4 ± 2.2 13.6 ± 1.3 13.7 ± 1.8 15.2 ± 1.4
CD8+ 38.6 ± 1.7 36.6 ± 2.0 37.0 ± 0.7 35.0 ± 3.3
Naive 53.0 ± 3.7 58.7 ± 4.7 55.3 ± 4.4 61.2 ± 5.5
Memory 9.5 ± 1.2 7.9 ± 1.5 9.0 ± 1.6 8.4 ± 2.3
CD4− CD8− 5.0 ± 0.4 4.7 ± 0.5 4.7 ± 0.2 5.0 ± 0.8
CD11c+ DCs 4.2 ± 0.3 3.9 ± 0.2 4.2 ± 0.7 3.5 ± 0.3
pDCs 22.1 ± 2.3 23.4 ± 2.5 19.8 ± 1.6 24.3 ± 3.1
cDC 77.6 ± 2.3 76.2 ± 2.5 79.8 ± 1.6 75.2 ± 3.0
cDC1 (CD11b−) 41.1 ± 8.9 34.4 ± 1.3 32.3 ± 0.9 35.5 ± 3.0
cDC2 (CD11b+) 40.5 ± 5.4 39.9 ± 2.9 45.8 ± 1.3 38.2 ± 2.6
Ly6G+ Ly6C− granulocytes 2.8 ± 0.7 2.5 ± 0.9 1.3 ± 0.1 1.7 ± 0.3
Ly6G− Ly6C+ monocytes 2.4 ± 0.6 2.8 ± 0.1 3.3 ± 0.2 2.7 ± 0.4
Ly6Clow alternative
monocytes
41.7 ± 7.1 30.9 ± 9.3 48.0 ± 2.1 35.3 ± 6.5
Ly6Chigh classical
monocytes
21.8 ± 7.9 31.2 ± 4.3 13.8 ± 2.6 21.5 ± 3.9
Data are mean ± SD of four mice per group and expressed as percentage of total cells
(B220+, CD3+, CD11c+, Ly6G+ Ly6C−, Ly6G− Ly6C+) or percentage of parental cells.
Spleen weights were 103.8 ± 10.3, 119.3 ± 20.0, 94.5 ± 7.5, and 108.8 ± 10.0mg for
SIRT2/3+/+, SIRT2−/−, SIRT3−/−, and SIRT2/3−/− mice. Gray background: P < 0.05
vs. SIRT2/3+/+ mice.
macrophages with homeostatic functions and represent the main
macrophage population (90% of all macrophages) expressed
at baseline in the peritoneum. SPMs derived from blood
inflammatory monocytes quickly exceed LPMs upon infection
or inflammation (69). The peritoneal cavity of SIRT2/3−/−
mice contained 1.7-fold less NK cells, while the other leukocyte
subpopulations were not statistically significantly different
(Figure 2F). Beside a reduced number of NK cells, the MFI of
the activation marker CD43 expressed by NK cells was 1.3-fold
lower in SIRT2/3−/− mice (Figure 2G). Similar to what was
observed in the bone marrow and spleen, there was 1.8-fold
more B cells in the peritoneum of SIRT2/3−/− mice (Figure 2F).
B cells are divided into B1 (B-1a and B-1b) cells producing
natural antibodies and B2 cells (70). Interestingly, the peritoneal
cavity of SIRT2/3−/− mice contained proportionally more B-
1a cells and less B-1b cells than the one of SIRT2/3+/+ mice
(Figure 2H). This resulted in 3.3-fold more B-1a cells, 1.4-fold
more B-1b cells and subnormal number of B2 cells in SIRT2/3−/−
mice (SIRT2/3+/+ vs. SIRT2/3−/−: 0.9 ± 0.2 vs. 3.0 ± 0.5 ×
105 B-1a cells, 2.1 ± 0.8 vs. 3.0 ± 0.6 × 105 B-1b cells, 0.8 ±
0.4 vs. 1.9 ± 1.2 × 105 B-2 cells, P = 0.007, 0.05, and 0.08).
To substantiate the relevance of this observation, we quantified
IL-10, TNF and IL-6 production by peritoneal cells stimulated
ex vivo for 24 h with 10 ng/ml LPS (Figure 2I). SIRT2/3−/−
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FIGURE 2 | SIRT2/3−/− mice have minor alterations of blood and peritoneal leukocyte subpopulations. (A–E) Absolute number of CD45+ leukocytes (A) and
percentages of CD19+ B cells, CD3+ T cells, Ly6G+ PMNs, CD11b+Ly6G− monocytes and NK1.1+ NK cells (B) in peripheral blood of SIRT2/3+/+, SIRT2−/−,
SIRT3−/−, and SIRT2/3−/− mice. (C) Mean fluorescence intensity (MFI) of CD11b expressed by SIRT2/3+/+ and SIRT2/3−/− PMNs. (D) Percentage of Ly6C low,
(Continued)
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FIGURE 2 | intermediate and high expressing monocytes. (E) MFI of CD62L expressed by blood SIRT2/3+/+ and SIRT2/3−/− NK cells. (F) Percentage of B cells, T
cells, large peritoneal macrophages (LPMs), small peritoneal macrophages (SPMs) and NK cells in the peritoneal cavity of SIRT2/3+/+ and SIRT2/3−/− mice. (G) MFI
of CD43 expressed by peritoneal SIRT2/3+/+ and SIRT2/3−/− NK cells. (H) Percentage of B-1a (CD23− CD5+), B-1b (CD23− CD5−) and B-2 (CD23+) cells among B
cells. (I) Peritoneal cells were exposed for 24 h to 10 ng/ml LPS. The concentrations of TNF, IL-6 and IL-10 in cell culture supernatants were measured by ELISA. Data
were obtained from eight (A–D) or four (E–I) mice per group. Each dot represents one mouse. *P < 0.05; ***P < 0.005. Gating strategies are presented in
Supplementary Figure 3 and in Heinonen et al. (52).
peritoneal cells produced more IL-10 and less TNF and IL-6 than
SIRT2/3+/+ peritoneal cells (P < 0.02 for IL-10). These results
were in line with the fact that B-1 cells, and particularly B-1a cells,
are considered to produce high levels of IL-10 at baseline and
upon microbial stimulation (70–72). The proportion of LPMs
was slightly reduced in the peritoneal cavity of SIRT2/3−/−
mice (Figure 2F). Overall, SIRT2/3 deficiency resulted in minor
organ-specific alterations of the main leukocyte subpopulations,
apart from an increased, functionally relevant, number of B-1a
cells in the peritoneum.
SIRT2/3 Deficiency Enhances Cytokine
Secretion, Phagocytosis, and Killing by
Macrophages
Previous studies demonstrated that the deletion of SIRT2 and
SIRT3 had no consequence on the expression of PRRs and
microbial product-induced cytokine production by immune cells
including BMDMs (13, 43). To test if SIRT2/3 deletion influenced
cytokine production, BMDMs were exposed to LPS, Pam3CSK4,
and CpG (i.e., agonists of TLR4, TLR1/2, and TLR9, respectively)
for 24 h before measuring the concentrations of TNF, IL-6
and IL-10 in cell culture supernatants (Figure 3A). SIRT2/3−/−
BMDMs produced significantly more TNF in response to LPS
and CpG, more IL-6 in response to LPS, Pam3CSK4 and CpG,
and more IL-10 in response to CpG. To test whether an
increased intracellular signaling was associated with increased
cytokine production, we quantified by Western blotting the
phosphorylation of ERK1/2 and p38 MAPKs and the nuclear
translocation of NF-κB p65 in BMDMs exposed to LPS for
0, 10, 30, and 60min (Figure 3B). SIRT2/3 double deletion
resulted in higher NF-κB p65 nuclear content at baseline and
increased phosphorylation of ERK1/2 after 30min of stimulation.
p38 was not differentially phosphorylated in SIRT2/3+/+ and
SIRT2/3−/− BMDMs. In line with the increased intracellular
signaling and cytokine production, the expression level of TLR1,
TLR2, TLR4, and TLR9 mRNA was increased in SIRT2/3−/−
BMDMs when compared to SIRT2/3+/+ BMDMs (Figure 3C).
Since SIRT2 deficiency promoted phagocytosis (13), we
compared the phagocytic activity over a period of 1 h of
SIRT2/3+/+ and SIRT2/3−/− BMDMs. The analysis by flow
cytometry of BMDMs incubated with fluorescent beads showed
a 1.4-fold higher proportion of SIRT2/3−/− BMDMs having
phagocytosed beads (P = 0.03; Figure 3D, left panel). To
better reflect infectious conditions, BMDMs were exposed
to live E. coli, and intracellular bacteria were quantified
by plating cell lysates followed by the enumeration of
colonies. SIRT2/3−/− BMDMs ingested 2.6-fold more E. coli
(SIRT2/3+/+ vs. SIRT2/3−/− BMDMs: 4.4 ± 2.5 vs. 11.3
± 4.8 × 104 E. coli, P = 0.03; Figure 3D, right panel).
The increased phagocytic activity of SIRT2/3−/− BMDMs was
independent from an increased expression of the phagocytic
receptors integrin αM/Itgam (CD11b), Itgβ1/Itgb1 (CD29),
Itgβ2/Itgb2 (CD18), Itgα5/Itga5 (CD49e), and ItgαX/Itgax
(CD11c) (Supplementary Figure 2A). Since a main function
of phagocytes is to kill invading microorganisms, we tested
the killing of E. coli by BMDMs following 6 h of incubation.
SIRT2/3−/− BMDMs showed around 2-fold more efficient
killing capacity when compared to SIRT2/3+/+ BMDMs as
demonstrated by a reduced percentage recovery of ingested
bacteria by SIRT2/3−/− BMDMs (SIRT2/3+/+ vs. SIRT2/3−/−
BMDMs: 25 ± 6 vs. 11 ± 2% recovery of ingested E. coli, P =
0.03; Figure 3E, left panel), and similar total numbers of bacteria
in SIRT2/3+/+ and SIRT2/3−/− BMDMs (9.3 vs. 1.2 × 104 total
E. coli, P = 0.5; Figure 3E, right panel).
SIRT2/3 Deficiency Alters Macrophage
Metabolism
Macrophages acquire energy mainly through oxidative
metabolism under steady-state and switch to glycolysis upon
activation (73, 74). Since SIRT2/3 deficiency increased the
cytokine response of BMDMs, though both proinflammatory
and anti-inflammatory cytokines, we assumed that their
glycolytic parameters were affected. The metabolic parameters
of SIRT2/3+/+ and SIRT2/3−/− BMDMs were measured using
the Seahorse technology. Unexpectedly, SIRT2/3−/− BMDMs
displayed reduced glycolysis, glycolytic capacity and glycolytic
reserve (Figure 4A). In line with this observation, SIRT2/3−/−
BMDMs expressed slightly reduced mRNA levels of Solute
carrier family 2, member 1 also known as Glucose transporter
1 (Glut1) while the mRNA levels of Hypoxia inducible factor
1α (Hif1a) were slightly increased (1.6-fold, Figure 4B). To
assess whether the lower glycolysis of SIRT2/3−/− BMDMs
was compensated by an increased metabolism of other sources
of energy, we assessed the dependency (i.e., the necessity for
a fuel to meet metabolic demand) and the flexibility (i.e., the
ability to increase the usage of fuel when access to other energy
sources is inhibited) of BMDMs toward glucose, fatty acids (FA)
and glutamine. SIRT2/3+/+ and SIRT2/3−/− BMDMs were
equally dependent and flexible toward glucose (Figure 4C).
However, SIRT2/3−/− BMDMs were less dependent than
SIRT2/3+/+ BMDMs toward FA and glutamine, but were more
flexible than SIRT2/3+/+ BMDMs toward FA (Figure 4C). FA
are metabolized in the mitochondria through FA oxidation
(FAO). FAO is controlled by the rate-limiting enzyme Carnitine
palmoyltransferase I (Cpt1) that facilitates FA transport to the
mitochondria (74). SIRT2/3−/− BMDMs expressed higher levels
of Cpt1 mRNA when compared to SIRT2/3+/+ BMDMs, but
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FIGURE 3 | SIRT2/3 deficiency increases cytokine secretion, phagocytosis and killing by macrophages. (A) BMDMs were exposed to LPS (10 ng/ml), Pam3CSK4
(100 ng/ml), and CpG (1µg/ml) for 24 h. The concentrations of TNF, IL-6, and IL-10 in cell culture supernatants were measured by ELISA. (B) BMDMs were exposed
for 0, 10, 30, and 60min to 10 ng/ml LPS. Phosphorylation of ERK1/2 and p38, and nuclear translocation of NF-κB p65 were measured by Western blotting.
Representative blots are presented for ERK1/2 phosphorylation (Full blots are available in Supplementary Figure 1). Quantitative data are means ± SD of three
mice. (C) Tlr1, Tlr2, Tlr4, and Tlr9 mRNA levels in BMDMs were quantified by RT-qPCR and normalized to actin mRNA levels. Data are mean ± SD of four mice
analyzed in triplicate. (D) Phagocytosis by BMDMs exposed for 1 h to fluorescent beads (left) and live E. coli (right) at a bead or bacteria-to-cell ratio of 10:1. Data were
analyzed by flow cytometry and colony enumeration, respectively. (E) Killing of E. coli by BMDMs. The percentage of recovery (left) was calculated by dividing the
number of bacteria recovered after 6 h by the number of bacteria recovered after 1 h. Absolute counts are presented on the right. Data are mean ± SD of four mice
analyzed in triplicate. Each dot represents a mouse. *P < 0.05; **P < 0.01; ***P < 0.005.
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FIGURE 4 | SIRT2/3 deficiency alters macrophage metabolism. (A) The extracellular acidification rate (ECAR) of SIRT2/3+/+ and SIRT2/3−/− BMDMs was measured
using the Seahorse technology (left) and used to calculate the glycolysis, glycolytic capacity and glycolytic reserve (right). Glu, glucose; Oligo, oligomycin; 2-DG,
2-deoxyglucose. (B) Glut1 and Hif1a mRNA levels in BMDMs were quantified by RT-qPCR and normalized to actin mRNA levels. (C) Dependency and flexibility of
SIRT2/3+/+ and SIRT2/3−/− BMDMs toward glucose, fatty acids (FA) and glutamine. (D) Cpt1, Fabp4, Hmgcr, Mvd and Sqle mRNA levels in BMDMs were quantified
by RT-qPCR and normalized to actin mRNA levels. (E) Glucose consumption and lactate production by SIRT2/3+/+ and SIRT2/3−/− BMDMs left unstimulated or
stimulated for 8 h (glucose) or 24 h (lactate) with 10 ng/ml LPS. Glucose and lactate were detected using a luminescence-based assay. (F) Nos2 and Arg1 were
quantified by RT-qPCR and normalized to actin mRNA levels. Data are means ± SD of 3–5 mice analyzed in triplicate. *P < 0.05; **P < 0.01; ***P < 0.005.
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lower levels of mRNA encoding for carrier protein and enzymes
involved in cholesterol synthesis FA binding protein 4 (Fabp4),
3-Hydroxy-3-methylglutaryl-coenzyme A reductase (Hmgcr),
Mevalonate decarboxylase (Mvd), and Squalene epoxidase (Sqle)
(Figure 4D). Therefore, SIRT2/3 deficiency possibly favored
FAO over cholesterol synthesis.
LPS stimulation induces macrophage polarization toward
a classical, M1, phenotype which is linked to a metabolic shift
from oxidative phosphorylation to glycolysis (73, 74). Thus,
we measured the consumption of glucose and the production
of lactate upon LPS stimulation. Glucose concentration in
medium decreased when BMDMs were exposed for 8 h to
LPS, with a slightly superior effect observed with SIRT2/3−/−
BMDMs (Control vs. LPS: P= 0.2 and 0.008 for SIRT2/3+/+ and
SIRT2/3−/− BMDMs; Figure 4E). In line with a metabolic shift,
the levels of lactate increased in the medium of LPS-simulated
BMDMs (Figure 4E). Overall, glucose consumption and
lactate production were not different between SIRT2/3+/+ and
SIRT2/3−/− BMDMs. Although these results were unanticipated
considering ECAR measurements, they could also reflect the
small increase in the production of both proinflammatory
and anti-inflammatory cytokines by double knockout BMDMs
exposed to LPS. Finally, we questioned whether SIRT2/3−/−
altered macrophage polarization by measuring the mRNA
expression levels of Nitric oxide synthase 2 (Nos2) and Arginase
1 (Arg1) as markers of M1 and M2 phenotypes, respectively.
SIRT2/3−/− macrophages expressed higher levels of Nos2 and
lower levels of Arg1 at baseline, but similar levels of both mRNAs
after stimulation with LPS (Figure 4F).
SIRT2/3−/− Mice Are Protected From
Endotoxic Shock
Acute inflammation induced by LPS is characterized by an early
anabolic glycolytic phase followed by a catabolic adaptation phase
involving FAO (50). SIRT2−/− and SIRT3−/− mice were shown
to behave like wild-type mice in models of endotoxemia (13,
43). Yet, considering that SIRT2/3−/− BMDMs stimulated with
microbial products produced more proinflammatory and anti-
inflammatory cytokines, and that the peritoneum of SIRT2/3−/−
mice contained more anti-inflammatory B-1a cells and less
activated NK cells, we hypothesized that SIRT2/3 deficiency may
protect mice from acute inflammation. A model of endotoxic
shock was developed by challenging mice intraperitoneally
with 10 mg/kg LPS. While 93% of SIRT2/3−/− mice survived
endotoxemia, only 58% of SIRT2/3+/+ mice did (P = 0.004;
Figure 5A). In agreement, SIRT2/3−/− mice showed lower
severity scores than SIRT2/3+/+ mice (Figure 5B), but there was
no noticeable differential effect on mouse weight (Figure 5C).
Depletion of macrophages by clodronate liposomes injected i.p.
(90% depletion, n = 4; P < 0.001) did not modify the survival
profiles (P = 0.6), suggesting a minor impact of macrophages in
our model. To assess the immune status of endotoxemic mice,
blood was collected 1 day post-challenge to quantify cytokines
(Figure 5D) and leukocyte subpopulations (Figure 5E). Nine
out of the fourteen detectable cytokines measured by Luminex
(IFNγ, IL-6, IL-10, IL-12p40, IL-17A, IL-18, KC/CXCL1, MIP-
2/CXCL2, IP-10/CXCL10) were present at significantly lower
concentrations in the blood of SIRT2/3−/− mice. Endotoxemia
was associated with a strong reduction of all blood leukocyte
subpopulations (Figure 5E). Finally, we questioned whether
SIRT2/3 deletion would affect endotoxin tolerance as reported for
other sirtuins (24, 75–77). To address that question, blood was
collected from mice challenged 0, 1, 3, and 7 days earlier with
LPS. Blood was used to quantify leukocytes and to measure TNF
and IL-10 response upon ex vivo exposure for 6 h to 10 ng/ml
LPS or 10µM CpG. At baseline, the blood of SIRT2/3−/− mice
contained slightly more leukocytes (Figure 5F) and produced
more TNF and IL-10 in response to LPS and CpG stimulation
(Figure 5G). Confirming the induction of endotoxin tolerance,
TNF production induced by LPS and CpG was decreased while
IL-10 production induced by LPS was enhanced when comparing
the reactivity of blood from SIRT2/3+/+ and SIRT2/3−/− mice
challenged 1 day earlier with LPS with that of untouched
mice (Figure 5G). The production of TNF and IL-10 returned
roughly to those measured under baseline conditions using blood
collected from mice challenged 1 week earlier with LPS. Overall,
SIRT2/3 double deletion did not seem to affect the induction of
endotoxin tolerance.
DISCUSSION
Sirtuins share structural and functional features and shuttle
between cellular compartments. Hence they may compensate
the absence of one sirtuin in single knockout mice. Here,
we described a germinal SIRT2/3 double deficient mouse line.
We elected to delete SIRT2 and SIRT3 because SIRT2 is the
overall most expressed sirtuin and SIRT3 the predominant
mitochondrial sirtuin in myeloid cells (13, 43). The new
SIRT2/3−/− mouse line developed normally without apparent
defects. Yet, SIRT2/3 deficiency altered to some extent the
frequency of immune cells in several immune compartments
and the metabolism and functions of macrophages. Importantly,
SIRT2/3−/− mice were protected from endotoxemia, contrary to
SIRT2−/− and SIRT3−/− mice that behaved like wild-type mice
(13, 43). Altogether, these data suggest a subtle, concerted role
for SIRT2 and SIRT3 to be considered when developing drugs
targeting multiple sirtuins.
Additive or synergistic effects between SIRT2 and SIRT3 could
be anticipated since, for example, both SIRT2 and SIRT3 impact
on ROS detoxification albeit through different transcriptional
and post-transcriptional mechanisms, and both have been
reported to dampen inflammatory responses (13, 23–31, 38,
39, 41–44). However, most of the effects observed here were
rather slight. The most consistent effect of SIRT2/3 deficiency
on immune cell distribution was on B cells that were increased
slightly in the bone marrow, the spleen, the blood and more
strongly in the peritoneum. Whether these variations impact on
the development of plasma cells and humoral responses will be
addressed in future studies. An impact on the levels of natural
antibodies might be expected since B-1a cells are main producers
of natural polyreactive IgM antibodies biased toward bacterial
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FIGURE 5 | SIRT2/3−/− mice are protected from endotoxic shock. Mice were challenged with 10 mg/kg LPS i.p. Survival (A), severity score (B), and weight loss (C)
were recorded daily. Data are mean ± SD (B,C). (D–G) Blood was collected 0, 1, 3, and 7 days post-challenge to quantify the concentrations of cytokines by Luminex
(D, at day 1 post-challenge) and leukocytes by flow cytometry (E,F, at day 1 post-challenge in E). Blood collected 0, 1, 3, and 7 days post-LPS challenge was
stimulated ex vivo for 6 h with 10 ng/ml LPS and 10µM CpG. TNF and IL-10 concentrations were measured by ELISA (G). TNF and IL-10 concentrations in blood
cultured for 6 h without stimulation were below the detection limit (not depicted on the graphs). Data were obtained from 26 (A), 7–8 (B,C,F,G), 4 (D), and 14–16 (E)
mice per group. *P < 0.05; **P < 0.01; ***P < 0.005.
and self-antigens (70). Considering that B-1 B cells cooperate
to protect from pneumococcal diseases through the generation
of anti-streptococcal natural antibodies by B-1a cells and the
generation of acquired anticapsule response by B-1b cells (78), it
will be interesting to test whether SIRT2/3−/− mice are resistant
to Streptococcus pneumoniae pneumonia (79).
The bone marrow of SIRT3−/− mice, but not SIRT2−/−
mice, contained more B cells. Up to now, the role of
sirtuins in B cell biology has been mainly studied using
B cell lymphoma giving rise to contrasting observations.
Overexpression of SIRT1 and SIRT2 promoted the survival
of chronic lymphocytic leukemia (CLL) B cells and correlated
with poor outcome in patients with CLL (80, 81). On the
contrary, SIRT3 acts as a tumor suppressor since reduced
SIRT3 expression was associated with B cell proliferation and
worsening of patients with B cell malignancies (82). However,
sirtuins may have a differential impact on malignant cells and
primary cells.
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Additional leukocyte subsets were affected in SIRT2/3−/−
mice, however with small organ specific effects, for example
a reduced proportion of alternative monocytes in the bone
marrow and spleen, of PMNs in the blood and spleen and of
DCs in the spleen. In general, these effects were observed in
one of the two parental mouse lines (SIRT2−/− or SIRT3−/−
mice), indicative of dominant effects of the knockouts. A more
robust effect was observed on NK cells. The expression of
sirtuins in NK cells has not been reported, but the fact that
caloric restriction modulated NK cell phenotype suggested that
sirtuins may impact on NK cell development or functions
(83). NK cells from the blood of SIRT2−/−, SIRT3−/−, and
SIRT2/3−/− mice showed increased expression of the homing
receptor CD62L, while the peritoneum of SIRT2/3−/− mice
contained less NK cells with reduced expression of CD43.
CD43 is a maturation marker of NK cells, and reduced CD43
expression reflects decreased IFNγ production by NK cells
(84). Thus, in the peritoneum, SIRT2/3−/− NK cells potentially
display a reduced inflammatory profile. It will be interesting
to assess the functional consequences of SIRT2/3 deficiency
on NK cell-mediated immunity, for instance in models of
viral infections induced by murine cytomegalovirus (MCMV),
lymphocytic choriomeningitis virus (LCMV) or influenza virus
during which NK cells play a protective role. Whether SIRT2/3
deficiency affects NK cell antitumor cell cytotoxicity and has a
role in graft-vs-host-disease would be additional interesting areas
of investigations.
We previously reported that SIRT2−/− and SIRT3−/−
BMDMs produced normal levels of a large panel of cytokines (13,
43). Conversely, SIRT2/3−/− BMDMs produced increased levels
of both proinflammatory (TNF, IL-6) and anti-inflammatory
(IL-10) cytokines when compared to control BMDMs. A
plausible mechanism underlying augmented cytokine response
was the increased activation of ERK1/2 and NF-κB p65
intracellular signaling in SIRT2/3−/− BMDMs. Like SIRT2−/−
BMDMs (13), SIRT2/3−/− BMDMs phagocytosed better inert
beads and live bacteria than control BMDMs. Moreover,
they killed ingested E. coli to a higher rate. Of note,
divergent observations have been reported in the literature,
with SIRT2 and SIRT3 associated with both anti-inflammatory
and proinflammatory activities also in macrophages (13,
23–31, 41–44). As an example of a possible antagonism
between SIRT2 and SIRT3, silencing SIRT2 reduced NF-
κB activation and induced macrophage alternative (anti-
inflammatory) activation (85) while SIRT3 upregulation reduced
macrophage inflammatory responses (86). This dichotomy
might explain the mixed phenotype of SIRT2/3−/− BMDMs
which displayed characteristics of classically and alternatively
activated macrophages.
Sirtuins are intrinsically linked to cell metabolism. The
deletion of SIRT2 and SIRT3 stimulated HIF-1α expression and
activity, thereby promoting Glut1 expression, glucose uptake
and tumor growth (87, 88). In line, Hif1a mRNA levels
were increased 1.6-fold in SIRT2/3−/− BMDMs. However,
this increase did not translate into an increase of glucose
metabolism since Glut1 expression and glycolytic parameters,
measured using the Seahorse technology, were all reduced in
SIRT2/3−/− BMDMs. This was surprising since inflammatory
cytokine response is normally supported by glycolysis. Yet
one has to take into account that SIRT2/3−/− BMDMs
were not purely “proinflammatory” since they increased IL-
10 production, which in alternatively activated macrophages is
fueled by oxidative phosphorylation (73). Nonetheless, glucose
consumption and lactate production measured by luminescent
assays were not affected in SIRT2/3−/− BMDMs. Differences
in the time point analyzed, plastic support and medium used
for cell culture in relation with the technology used may
have affected metabolic measurements. Overall, dual deletion
of SIRT2 and SIRT3 may have disrupted metabolic control in
BMDMs. A possible explanation for our observations is that
post-translational mechanisms destabilized HIF-1α and impaired
its transcriptional activity in SIRT2/3−/− BMDMs. Attractive
mediators could be SIRT6 and SIRT7 which expression was
enhanced to some extent in SIRT2/3−/− BMDMs. Indeed, SIRT6
functions as a co-repressor of HIF-1α, and SIRT7 inhibits
the activity of HIF-1α through a mechanism independent
of proteasomal or lysosomal degradation of HIF-1α (89,
90). SIRT2/3−/− BMDMs were less dependent on FA and
glutamine but more flexible toward FA, indicating that both
glycolysis and FA metabolism were altered in SIRT2/3−/−
BMDMs. The expression of genes essential for the cholesterol
synthesis pathway was decreased in SIRT2/3−/− BMDMs,
signifying that SIRT2/3 deficiency influenced lipid metabolism
of macrophages by favoring FAO over cholesterol synthesis.
Although counterintuitive at first glance, a similar antagonism
between FAO and cholesterol synthesis has been observed in
macrophages deficient in carnitine palmitoyltransferase 1 and 2
(CPT1, CPT2) (91).
Metabolic adaptation shapes immune cell functions and
influences the acute phase and the resolution phase of
inflammation that are fueled predominantly by glycolysis and
oxidative phosphorylation, respectively (92, 93). Indeed, mice
treated with 2-deoxyglucose to block glycolysis or with the
sirtuin inhibitor cambinol were protected from endotoxemia
(94, 95). Going well along with a reduced glycolytic activity of
macrophages in vitro, SIRT2/3−/− mice had a strong survival
advantage during endotoxemia, which was associated with
reduced blood levels of cytokines. Even so, SIRT2/3 double
deletion did not seem to affect endotoxin tolerance as reported
for SIRT1, SIRT4, and SIRT5 (24, 75–77). Interestingly, SIRT6,
together with SIRT1, coordinated the switch from glucose
to FAO during the acute inflammatory response (50), and
transcriptional activation of SIRT6 via FOXO3a inhibited the
Warburg effect in glioblastoma cells (96). Consequently, the
increased expression of SIRT6 in SIRT2/3−/− macrophages
may favor FAO and contribute to dampen the cytokine
storm involved in the pathological process of endotoxemia.
An additional possibility is about a role played by B-1a
cells, which were around 3-times more numerous in the
peritoneum of SIRT2/3−/− mice. Indeed, B-1a cells are an
important source of IL-10 and may circumvent local cytokine
burst in response to LPS challenge. Further, B-1a cells were
shown to protect mice from experimental sepsis (97, 98).
Finally, peritoneal NK cells in SIRT2/3−/− mice were not
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only less, but also likely less activated as pinpointed by a
reduced expression of CD43. As a consequence, the NK
compartment potentially produced reduced levels of IFNγ
which was shown to strongly potentiate TNF production
and mortality during experimental endotoxemia (84, 99,
100). Altogether, several factors likely contributed to reduce
systemic inflammatory parameters, morbidity and mortality of
SIRT2/3−/− endotoxemic mice.
Overall, we report that SIRT2/3 dual deletion revealed
a phenotype not observed in single deficient mice,
indicating that sirtuins act in concert or compensate
each other for certain immune functions. Considering
the link between SIRT2 and SIRT3, metabolism and
age-associated dysfunctions, it will be of great interest
to investigate the impact of SIRT2/3 deficiency in the
pathogenesis of metabolic, oncologic, neurodegenerative
and chronic inflammatory disorders. Importantly from a
translational perspective, SIRT2/3−/− mice were protected
from endotoxemia. Thus, inhibitors targeting multiple
sirtuins developed for clinical purposes may be useful to
treat inflammatory diseases.
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